Sugi Predict

Sugi Predict / Compounds / SCHEMBL20011908

SCHEMBL20011908

SCHEMBL20011908

CC(C)(C)OC(=O)N1CCN(c2nc(I)nc(Cl)c2Cl)CC(F)(F)C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.37
▸ GBA1 P04062 2/20 0.35
▸ CKS1B P61024 1/20 0.35
▸ SKP1 P63208 1/20 0.35
▸ SKP2 Q13309 1/20 0.35
▸ PDK2 Q15119 1/20 0.35
▸ CYP11B2 P19099 1/20 0.35
▸ CYP3A4 P08684 2/20 0.35
▸ CYP3A5 P20815 2/20 0.35
▸ BACE1 P56817 1/20 0.35
▸ CNR2 P34972 2/20 0.35
▸ SUV39H2 Q9H5I1 1/20 0.35
▸ MEN1 O00255 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ STS P08842 1/20 0.34
▸ ALDH1A1 P00352 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ MAPT P10636 1/20 0.34
▸ MAP4K4 O95819 1/20 0.34
▸ GRIA1 P42261 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30062956 1.00 POLB (0.37) POLBGBA1CKS1BSKP1SKP2
SCHEMBL20012043 0.88 POLB (0.38) POLBGBA1CKS1BSKP1SKP2
SCHEMBL20139189 0.80 GBA1 (0.38) POLBGBA1CKS1BSKP1SKP2
SCHEMBL30234939 0.80 GBA1 (0.38) POLBGBA1CKS1BSKP1SKP2
SCHEMBL30063195 0.77 GPR119 (0.46) POLBGBA1CKS1BSKP1SKP2
SCHEMBL20011907 0.77 GPR119 (0.46) POLBGBA1CKS1BSKP1SKP2
SCHEMBL30060981 0.77 GBA1 (0.40) POLBGBA1CKS1BSKP1SKP2
SCHEMBL20154093 0.75 POLB (0.34) POLBGBA1CKS1BSKP1SKP2
SCHEMBL20154073 0.75 SMARCA2 (0.42) POLBMEN1KMT2ASTSLMNA
SCHEMBL20154090 0.75 SMARCA2 (0.42) POLBMEN1KMT2ASTSLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-26 — — US disclosed
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-26 — — US disclosed
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2023-09-26 — — US disclosed
CN-110088100-B Pyrimidone derivatives as CDC7 inhibitors 癌症研究科技有限公司 2023-02-17 — — CN disclosed
CN-110036006-B Preparation and use of pyrimidinone derivatives 癌症研究科技有限公司 2022-12-13 — — CN disclosed
US-20220079942-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2022-03-17 — — US disclosed
US-11020396-B2 Pyrimidinone derivatives as Cdc7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-06-01 — — US disclosed
US-11020396-B2 Pyrimidinone derivatives as Cdc7 inhibitors CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-06-01 — — US disclosed
EP-3538523-B1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECH LTD (GB) 2021-05-19 — — EP disclosed
EP-3538523-B1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECH LTD (GB) 2021-05-19 — — EP disclosed
US-10919896-B2 Preparation and uses of pyrimidinone derivatives CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-02-16 — — US disclosed
EP-3515903-B1 PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES CANCER RESEARCH TECH LTD (GB) 2020-10-21 — — EP disclosed
EP-3515903-B1 PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES CANCER RESEARCH TECH LTD (GB) 2020-10-21 — — EP disclosed
US-20200123157-A1 PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. 2020-04-23 — — US disclosed
US-20200123157-A1 PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE TEVA BRANDED PHARMACEUTICAL PRODUCTS R&D, INC. 2020-04-23 — — US disclosed
US-20190336502-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2019-11-07 — — US disclosed
EP-3538523-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS Cancer Research Technology Limited (GB) 2019-09-18 — — EP disclosed
WO-2018087527-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-17 — — WO disclosed
WO-2018087527-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-05-17 — — WO disclosed
WO-2018055402-A1 PREPARATION AND USES OF PYRIMIDINONE DERIVATIVES CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-03-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190336502-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CDC7, CDK7, CDK17 POLB 254/4885GBA1 3480/4885CKS1B 64/4885
US-11766434-B2 Pyrimidinone derivatives as CDC7 inhibitors CDC7, CDK7, CDK17 POLB 254/4885GBA1 3480/4885CKS1B 64/4885
US-20220079942-A1 PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS CDC7, CDK7, CDK17 POLB 254/4885GBA1 3480/4885CKS1B 64/4885
US-10919896-B2 Preparation and uses of pyrimidinone derivatives CDC7, CDK7, CDK17 POLB 188/4885GBA1 3433/4885CKS1B 47/4885
US-11020396-B2 Pyrimidinone derivatives as Cdc7 inhibitors CDC7, CDK7, CDK17 POLB 254/4885GBA1 3480/4885CKS1B 64/4885
US-20200123157-A1 PREPARATION AND USES OF PYRIMIDINONE DERIVATIVE CDC7, CDK7, CDK17 POLB 198/4885GBA1 3457/4885CKS1B 45/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.